Key Details
Annual ROE
-107.78%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Aug 08, 2023Recent annual earnings:
Mar 23, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
24 Mar '23 Mizuho
Neutral23 Mar '23 EF Hutton
Hold09 Mar '23 Jefferies
Underperform08 Mar '23 Truist Securities
Hold07 Mar '23 HC Wainwright & Co.
Neutral06 Jan '23 Piper Sandler
Overweight05 Jan '23 EF Hutton
Hold21 Nov '22 HC Wainwright & Co.
Buy08 Nov '22 SVB Leerink
Market Perform19 May '22 HC Wainwright & Co.
BuyScreeners with TCRR included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
TCR2 Therapeutics doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of TCR2 Therapeutics?
- What is the ticker symbol for TCR2 Therapeutics?
- Does TCR2 Therapeutics pay dividends?
- What sector is TCR2 Therapeutics in?
- What industry is TCR2 Therapeutics in?
- What country is TCR2 Therapeutics based in?
- When did TCR2 Therapeutics go public?
- Is TCR2 Therapeutics in the S&P 500?
- Is TCR2 Therapeutics in the NASDAQ 100?
- Is TCR2 Therapeutics in the Dow Jones?
- When was TCR2 Therapeutics's last earnings report?
- When does TCR2 Therapeutics report earnings?
- Should I buy TCR2 Therapeutics stock now?
What is the primary business of TCR2 Therapeutics?
TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. Its lead product candidate is gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin-expressing solid tumors, which is in Phase 1/2 clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma and acute myeloid leukemia. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What is the ticker symbol for TCR2 Therapeutics?
The ticker symbol for TCR2 Therapeutics is NASDAQ:TCRR
Does TCR2 Therapeutics pay dividends?
No, TCR2 Therapeutics does not pay dividends
What sector is TCR2 Therapeutics in?
TCR2 Therapeutics is in the Healthcare sector
What industry is TCR2 Therapeutics in?
TCR2 Therapeutics is in the Biotechnology industry
What country is TCR2 Therapeutics based in?
TCR2 Therapeutics is headquartered in United States
When did TCR2 Therapeutics go public?
TCR2 Therapeutics's initial public offering (IPO) was on 14 February 2019
Is TCR2 Therapeutics in the S&P 500?
No, TCR2 Therapeutics is not included in the S&P 500 index
Is TCR2 Therapeutics in the NASDAQ 100?
No, TCR2 Therapeutics is not included in the NASDAQ 100 index
Is TCR2 Therapeutics in the Dow Jones?
No, TCR2 Therapeutics is not included in the Dow Jones index
When was TCR2 Therapeutics's last earnings report?
TCR2 Therapeutics's most recent earnings report was on 8 August 2023
When does TCR2 Therapeutics report earnings?
The date for TCR2 Therapeutics's next earnings report has not been announced yet
Should I buy TCR2 Therapeutics stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions